CytoDyn Inc. Files S-1 Registration Statement

TL;DR

<b>CytoDyn Inc. has filed an S-1 registration statement, providing updated corporate and financial information.</b>

AI Summary

CytoDyn Inc. (CYDY) filed a IPO Registration (S-1) with the SEC on February 7, 2024. CytoDyn Inc. filed an S-1 registration statement on February 7, 2024. The filing indicates a fiscal year end of May 31. The company's principal business address is in Vancouver, WA. CytoDyn Inc. was formerly known as Rexray Corp. The SIC code for the company is Pharmaceutical Preparations [2834].

Why It Matters

For investors and stakeholders tracking CytoDyn Inc., this filing contains several important signals. This S-1 filing is a crucial step for potential future equity offerings, allowing the company to raise capital. The document provides a comprehensive overview of the company's business, financial condition, and risks, which is essential for investors to assess its value and prospects.

Risk Assessment

Risk Level: medium — CytoDyn Inc. shows moderate risk based on this filing. The company's S-1 filing suggests it is preparing for potential equity offerings, which can be dilutive to existing shareholders if not managed effectively. The lack of specific financial performance data in the provided snippet also contributes to a medium risk assessment.

Analyst Insight

Investors should closely monitor future filings for details on any proposed equity offerings and the company's financial performance to assess potential dilution and growth opportunities.

Financial Highlights

revenue

836528000

total Assets

958988000

total Debt

941191000

Key Numbers

• 2024-02-07 — Filing Date (S-1 Registration Statement)
• 0531 — Fiscal Year End (Company's fiscal year end)
• 360-980-8524 — Business Phone (CytoDyn Inc. contact number)
• 2003-11-14 — Name Change Date (From CYTODYN INC to previous name)
• 2002-06-17 — Name Change Date (From REXRAY CORP to CYTODYN INC)

Key Players & Entities

• CytoDyn Inc. (company) — Filer name
• S-1 (regulator) — Form type
• 0001558370-24-000836 (document) — Accession number
• 20240207 (date) — Filing date
• Vancouver, WA (location) — Business address
• Rexray Corp (company) — Former company name
• 2834 (industry) — Standard Industrial Classification
• 0531 (date) — Fiscal year end

Forward-Looking Statements

• Increased selling pressure on CytoDyn's stock due to registered shares hitting the market. (CytoDyn Inc. (CYDY)) — high confidence, target: Q2 2024

FAQ

Industry Context

CytoDyn Inc. operates within the pharmaceutical preparations industry, focusing on the development and commercialization of therapeutic products.

Regulatory Implications

As a pharmaceutical company, CytoDyn Inc. is subject to regulatory oversight from bodies like the FDA, which governs drug approval and manufacturing processes.

What Investors Should Do

1. Review the full S-1 filing for detailed financial statements and management discussion.
2. Analyze the company's pipeline and clinical trial progress for future revenue potential.
3. Assess the competitive landscape and regulatory hurdles for CytoDyn's products.

Year-Over-Year Comparison

This is an S-1 filing, which is typically an initial registration statement for securities. Therefore, direct comparison to a prior filing of the same type is not applicable without more context on previous filings.

Key Financial Figures

• $0.001 — 7 shares of our common stock, par value $0.001 per share (the "common stock"), and 105
• $0.18 — e closing price of our common stock was $0.18 per share. Investing in our securities
• $0.50 — common stock with an exercise price of $0.50 per share, for total proceeds of approx
• $3.4 million — re, for total proceeds of approximately $3.4 million. The warrants issued in these transacti
• $0.16 — The warrants have an exercise price of $0.16 per share and include a cashless exerci
• $2.3 million — egate principal amount of approximately $2.3 million ("Placement Agent Notes"). The Placemen
• $0.26 — The warrants have an exercise price of $0.26 per share and include a cashless exerci
• $0.306 — common stock with an exercise price of $0.306 per share. The warrants issued in these
• $3.3 million — re, for total proceeds of approximately $3.3 million. The warrants issued in these transacti
• $1.00 — common stock with an exercise price of $1.00 per share, for total proceeds of approx
• $11.4 million — re, for total proceeds of approximately $11.4 million. The warrants issued in these transacti
• $21.8 million — re, for total proceeds of approximately $21.8 million. The warrants issued in these transacti
• $0.255 — 23,515 shares have an exercise price of $0.255 per share . The warrants include a cash
• $38.2 m — receive proceeds of up to approximately $38.2 million, as further described in " Use of

Filing Documents

• cydy-20240130xs1.htm (S-1) — 5811KB
• cydy-20240130xex3d1.htm (EX-3.1) — 286KB
• cydy-20240130xex4d1.htm (EX-4.1) — 28KB
• cydy-20240130xex5d1.htm (EX-5.1) — 10KB
• cydy-20240130xex23d1.htm (EX-23.1) — 3KB
• cydy-20240130xexfilingfees.htm (EX-FILING FEES) — 54KB
• cydy-20240130xs1008.jpg (GRAPHIC) — 16KB
• cydy-20240130xex3d1001.jpg (GRAPHIC) — 4KB
• cydy-20240130xex5d1001.jpg (GRAPHIC) — 9KB
• cydy-20240130xex5d1002.jpg (GRAPHIC) — 6KB
• cydy-20240130xex5d1003.jpg (GRAPHIC) — 7KB
• cydy-20240130xex5d1004.jpg (GRAPHIC) — 2KB
• 0001558370-24-000836.txt (&nbsp;) — 22930KB
• cydy-20240130.xsd (EX-101.SCH) — 125KB
• cydy-20240130_cal.xml (EX-101.CAL) — 78KB
• cydy-20240130_def.xml (EX-101.DEF) — 664KB
• cydy-20240130_lab.xml (EX-101.LAB) — 797KB
• cydy-20240130_pre.xml (EX-101.PRE) — 1053KB
• cydy-20240130xs1_htm.xml (XML) — 3161KB

USE OF PROCEEDS

USE OF PROCEEDS 20 MARKET FOR OUR COMMON STOCK AND DIVIDEND POLICY 21 OUR BUSINESS 22

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 42 MANAGEMENT 54 EXECUTIVE AND DIRECTOR COMPENSATION 57 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 63

SECURITY OWNERSHIP BY CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP BY CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 65 SELLING STOCKHOLDERS 66 PLAN OF DISTRIBUTION 72

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 74 SECURITIES ACT RESTRICTIONS ON RESALE OF SECURITIES 77 LEGAL MATTERS 78 EXPERTS 78 WHERE YOU CAN FIND MORE INFORMATION 78 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 In making your investment decision, you should rely only on the information contained in this prospectus. We have not authorized anyone to provide you with different or additional information. We are not making an offer to sell or seeking an offer to buy any shares of common stock in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is complete and accurate as of any date other than the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of securities offered hereby. ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 (the "Registration Statement") that we filed with the SEC. You should read this prospectus and the exhibits filed with or incorporated by reference in the Registration Statement carefully. Such documents contain important information you should consider when making your investment decision. See "Where You Can Find More Information" in this prospectus. This prospectus may be supplemented from time to time to add, update or change information in this prospectus. Any statement contained in this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in such prospectus supplement modifies or supersedes such statement. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. You may only rely on the information contained in this prospectus or that we have referred you to. We have not authorized anyone to provide you with different information. This prospectus does not constitute an

View Full Filing

View this S-1 filing on SEC EDGAR